Frontline Alectinib Approved in Europe for ALK-Positive NSCLC

December 22, 2017 – The European Commission (EC) has approved alectinib for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Roche, the manufacturer of the second-generation ALK inhibitor. The approval, which follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use, is based on findings from the phase III ALEX trial … (leggi tutto)